Related Experiment Video

Updated: Jun 25, 2026

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury

Published on: October 21, 2017

Significance of increased expression of decoy receptor 3 in chronic liver disease

S Kim1, V Kotoula, P Hytiroglou

  • 1BioPowerTech, Tuscaloosa, AL 35406, USA. sungheekim@ymail.com

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
|February 7, 2009
PubMed
Abstract

Insights

Decoy receptor 3 is expressed in chronic liver disease, potentially protecting liver cells from apoptosis. This finding may aid in understanding liver regeneration and preventing cirrhosis and cancer.

Area of Science:

  • Hepatology
  • Immunology
  • Cell Biology

Background:

  • Apoptosis is crucial in chronic liver disease, but regeneration mechanisms are unclear.
  • Molecules counteracting apoptosis may enhance liver cell survival.
  • Decoy receptor 3 (DcR3) inhibits apoptosis mediated by TNF-family ligands.

Purpose of the Study:

  • Investigate DcR3 expression in chronic liver diseases.
  • Determine DcR3's role in liver regeneration and disease progression.

Main Methods:

  • Immunohistochemistry and in situ hybridization on liver biopsies.
  • Analysis of liver biopsies from patients with varying fibrosis stages.

Main Results:

  • DcR3 protein and mRNA found in biliary epithelial cells and lymphocytes in diseased livers.
  • Intense DcR3 expression observed in regenerative and dysplastic nodules.
  • DcR3 secretion by hepatocellular carcinoma cells involves MAPK activation.

Conclusions:

  • DcR3 is specifically expressed in chronic liver disease and hepatocellular carcinoma.
  • DcR3 may promote liver cell survival via anti-apoptotic activity.
  • DcR3 plays a role in liver cirrhosis and hepatocarcinogenesis progression.

More Related Videos

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis06:46

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis

Published on: February 25, 2022

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...